SRR1516054
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.510
- MYC_TARGETS_V2+0.470
- G2M_CHECKPOINT+0.450
- MYC_TARGETS_V1+0.440
- E2F_TARGETS+0.420
- CHOLESTEROL_HOMEOSTASIS+0.410
- MITOTIC_SPINDLE+0.340
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.340
- ADIPOGENESIS+0.320
- GLYCOLYSIS+0.320
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- INFLAMMATORY_RESPONSE-0.340
- ANGIOGENESIS-0.330
- HEDGEHOG_SIGNALING-0.320
- MYOGENESIS-0.320
- IL6_JAK_STAT3_SIGNALING-0.300
- KRAS_SIGNALING_DN-0.250
- APICAL_SURFACE-0.200
- INTERFERON_GAMMA_RESPONSE-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516051 | — | — | 0.961 |
| 2 | SRR1516057 | — | — | 0.933 |
| 3 | SRR6013542 | — | cohortSQ1 | 0.919 |
| 4 | TCGA-CF-A3MG-01A-11R-A20F-07 | — | — | 0.894 |
| 5 | E3887082-4C43-426C-8580-ECAA4EFEC577 | — | — | 0.855 |
| 6 | MNG449 | — | — | 0.853 |
| 7 | 1764b9ab-4f37-47c5-8225-40c574433f40 | — | — | 0.847 |
| 8 | R122 | — | — | 0.845 |
| 9 | TCGA-DQ-7588-01A-11R-2081-07 | — | — | 0.845 |
| 10 | TCGA-CV-7180-01A-11R-2016-07 | — | — | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.510 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.450 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.410 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.340 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.320 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.320 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.300 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.250 | Inavolisib | — uncovered |
| PEROXISOME | 0.210 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |